Business Context and Reporting Period
Company: Research Solutions, Inc. (RSSS)
Filing Type: Form 8-K (Current Report)
Date of Report: November 24, 2023
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) to acquire Scite, Inc.
Key Financial Metrics and Transaction Terms
This filing details the structure of the acquisition rather than the company's historical financial performance. Key transaction metrics include:
- Base Closing Consideration: Approximately $13.72 million (subject to adjustments).
- Cash Component: Approximately $6.30 million deposited with Equiniti Trust Company, LLC.
- Stock Component: Approximately 2.73 million shares of Research Solutions, Inc. common stock reserved.
- Debt Payoff: Includes payoff of Scite's indebtedness and unpaid transaction expenses.
- Escrow and Holdbacks: $1.48 million in escrow; $0.15 million purchase price adjustment holdback; $0.025 million Optionholder Holdback.
- Earnout Structure: Calculated as (3.5 x Ending Annual Recurring Revenue) minus $13.72 million.
- Earnout Floor: Minimum earnout amount of $1.07 million.
- Earnout Payment Terms: Eight equal installments over eight quarters; 50% cash, 50% stock per installment.
Material Changes and Transaction Conditions
The filing announces a material change in corporate structure via the proposed merger of Scite, Inc. into a wholly-owned subsidiary of Research Solutions, Inc. Key conditions and limitations include:
- Closing Conditions: Subject to customary conditions, Scite stockholder approval, absence of material adverse effect, and delivery of closing documents.
- Shareholder Approval: No approval by Research Solutions, Inc. shareholders is required.
- Termination Rights: Either party may terminate if the merger is not consummated by December 1, 2023, or if closing conditions become incapable of fulfillment prior to that date.
- Consideration Caps:
- Cash Limitation: Cash portion cannot exceed 60% of the total merger consideration value.
- Stock Limitation: Stock issuance capped at 2.96 million shares.
- Buyer Share Cap: Issuance cannot exceed 19.99% of total issued and outstanding shares at closing.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release and FAQ document (Exhibits 99.1 and 99.2) issued on November 27, 2023, regarding the acquisition. The text emphasizes that the Merger Agreement contains representations and warranties made solely for the benefit of the parties and should not be relied upon as characterizations of the actual state of facts.
Risks and Contingencies:
- Timing Risk: The transaction faces a hard deadline of December 1, 2023, for consummation or termination.
- Approval Risk: Closing is contingent upon Scite obtaining required stockholder approval.
- Valuation Risk: Final consideration is subject to purchase price adjustments based on cash, net working capital, indebtedness, and transaction expenses at closing.
- Regulatory Status: Information in the press release and FAQ is furnished but not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the status of Scite's stockholder approval required for closing.
- Confirm the final purchase price adjustments regarding Scite's net working capital and indebtedness at closing.
- Monitor the December 1, 2023, deadline for potential termination of the agreement.
- Review the "Ending Annual Recurring Revenue" definition in the full Merger Agreement to understand the earnout calculation.
- Check the impact of the 19.99% Buyer Share Cap on the final number of shares issued to Scite shareholders.